Xiao-Lu Wang

Prof. Xiao-Lu Wang


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 August 2023 in The FASEB Journal
Verified
Journal Article
Open access
HWHongzhuang Wen
Hongzhuang Wen
CQChangbao Qu
Changbao Qu
ZWZhu Wang
Zhu Wang
HGHaitao Gao
Haitao Gao
WLWuyao Liu
Wuyao Liu
XWXiao-Lu Wang
Xiao-Lu Wang
Cuproptosis, a newly discovered programmed cell death induced by copper ions, is associated with the progression and drug resistance of various tumors. Docetaxel plays a vital role as a first‐line chemotherapeutic agent for advanced prostate cancer; however, most patients end up with prostate cancer progression because of inherent or acquired resistance. Herein, we examined the role of cuproptosis in the chemotherapeutic resistance of prostate cancer to docetaxel. We treated prostate cancer cell lines with elesclomol–CuCl 2 , as well as with docetaxel. We performed analyses of CCK8, colony formation tests, cell cycle flow assay, transmission electron microscopy, and mTOR signaling in treated cells, and treated a xenograft prostate cancer model with elesclomol–CuCl 2 and docetaxel in vivo, and performed immunohistochemistry and Western blotting analysis in treated tumors. We found that elesclomol–CuCl 2 could promote cell death and enhance chemosensitivity to docetaxel. Elesclomol–CuCl 2 induced cell death and inhibited the growth of prostate cancer cells relying on copper ions‐induced cuproptosis, not elesclomol. In addition, dihydrolipoamide S‐acetyltransferase (DLAT) was involved in cuproptosis‐enhanced drug sensitivity to docetaxel. Mechanistically, upregulated DLAT by cuproptosis inhibited autophagy, promoted G2/M phase retention of cells, and enhanced the sensitivity to docetaxel chemotherapy in vitro and in vivo via the mTOR signaling pathway. Our findings demonstrated that the cuproptosis‐regulated DLAT/mTOR pathway inhibited autophagy and promoted cells in G2/M phase retention, thus enhancing the chemosensitivity to docetaxel. This discovery may provide an effective therapeutic option for treating advanced prostate cancer by inhibiting the chemotherapeutic resistance to docetaxel.

17 October 2022 in The FASEB Journal
Verified
Journal Article
Closed access
AZAn‐Ning Zhao
An‐Ning Zhao
ZYZhan Yang
Zhan Yang
DWDan‐Dan Wang
Dan‐Dan Wang
BSBei Shi
Bei Shi
HZHong Zhang
Hong Zhang
CQChang‐Bao Qu
Chang‐Bao Qu

1 November 2020 in Genomics
Verified
Journal Article
Closed access
LGLei Gao
Lei Gao
JMJialin Meng
Jialin Meng
YZYong Zhang
Yong Zhang
JGJunfei Gu
Junfei Gu
ZHZhenwei Han
Zhenwei Han
SGShenglin Gao
Shenglin Gao

1 July 2022 in Research Square
Verified
Preprint
Open access
PDF file
HWHongzhuang Wen
Hongzhuang Wen
YZYong Zhang
Yong Zhang
ZYZhan Yang
Zhan Yang
ZZZhao Zhai
Zhao Zhai
MWMingshuai Wang
Mingshuai Wang
XWXiao-Lu Wang
Xiao-Lu Wang
Background: To develop a comprehensive model for predicting disease-free survival (DFS) in patients with localized clear cell renal cell carcinoma (ccRCC). Methods: A retrospective analysis of 612 patients was performed between 2010 and 2015.The least absolute shrinkage and selection operator (LASSO) Cox regression analysis was performed to identify significant predictors. Furthermore, the multivariate Cox regression analysis was performed to reconfirm risk factors, then the prognosis model was constructed. The Harrell’s concordance index (C-index) was conducted to assess the model’s accuracy for predicting DFS in localized ccRCC.Results: The lymphocyte-to-monocyte ratio (LMR) (HR: 1.04, P = 0.009), the Mayo Clinic stage, size, grade, and necrosis score (SSIGN) (HR: 1.36, P < 0.001) and Mayo adhesive probability score (MAPS) (HR: 1.99, P<0.001) were the significant risk factors screened by LASSO Cox regression and reconfirmed by multivariate Cox regression analysis in 44 variables. The LMR-SSIGN-MAPS model was constructed by combining the LMR, SSIGN, and MAPS. In the training and validation cohorts, the Harrell’s C-index was larger for the LMR-SSIGN-MAPS model (0.854, 0.848) than the SSIGN score (0.782, 0.772). The Kaplan-Meier survival analysis demonstrated the significant association between higher LMR-SSIGN-MAPS score and poorer DFS (P < 0.001) in the overall cohorts.Conclusions: The LMR-SSIGN-MAPS model which consists of preoperative inflammation biomarkers, perinephric adipose tissue image-based scoring system, and pathological features showed the strengths of easy-to-use and high predictability and might be also used as a promising prognosis model in predicting DFS for patients with localized ccRCC.

1 January 2023 in Videosurgery and Other Miniinvasive Techniques
Verified
Journal Article
Open access
HWHongzhuang Wen
Hongzhuang Wen
YZYong Zhang
Yong Zhang
ZYZhan Yang
Zhan Yang
ZZZhao Zhai
Zhao Zhai
ZHZhenwei Han
Zhenwei Han
XWXiao-Lu Wang
Xiao-Lu Wang
Introduction Prediction models are increasingly being used to predict outcomes after surgery, and such a model would be a precious tool for patients with clear cell renal cell carcinoma (ccRCC) after surgery. Aim: To develop a comprehensive model for predicting disease-free survival (DFS) in...

29 June 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
LGLei Gao
Lei Gao
JMJialin Meng
Jialin Meng
YZYong Zhang
Yong Zhang
JGJunfei Gu
Junfei Gu
ZHZhenwei Han
Zhenwei Han
XWXiao-Lu Wang
Xiao-Lu Wang
The dysregulation of RNA binding proteins (RBPs) play critical roles in the progression of several cancers. However, the overall functions of RBPs in prostate cancer (PCa) remain poorly understood. Therefore, we first identified 144 differentially expressed RBPs in tumors compared to normal tissues based on the TCGA dataset. Next, six RBP genes (MSI1, MBNL2, LENG9, REXO2, RNASE1, PABPC1L) were screened out as prognosis hub genes by univariate, LASSO and multivariate Cox regression and used to establish the prognostic signature. Further analysis indicated that high risk group was significantly associated with poor RFS, which was validated in the MSKCC cohort. Besides, patients in high risk group was closely associated with dysregulation of DNA damage repair pathway, copy number alteration, tumor burden mutation and low-respond to cisplatin (P < 0.001), bicalutamide (P < 0.001). Finally, three drugs (ribavirin, carmustine, carbenoxolone) were predicted using Connectivity Map. In summary, we identified a six-RBP gene signature and three candidate drugs against PCa, which may promote the individualized treatment and further improve the life quality of PCa patients.